US 8840886
Method of treating cancer with DLL4 antagonist and chemotherapeutic agent
granted A61KA61K2039/505A61K31/282
Quick answer
US patent 8840886 (Method of treating cancer with DLL4 antagonist and chemotherapeutic agent) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Sep 23 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K2039/505, A61K31/282, A61K31/337, A61K31/4745